Copper Metabolism and Cuproptosis: Molecular Mechanisms and Therapeutic Perspectives in Neurodegenerative Diseases

Abstract

Copper is an essential trace element, and plays a vital role in numerous physiological processes within the human body. During normal metabolism, the human body maintains copper homeostasis. Copper deficiency or excess can adversely affect cellular function. Therefore, copper homeostasis is stringently regulated. Recent studies suggest that copper can trigger a specific form of cell death, namely, cuproptosis, which is triggered by excessive levels of intracellular copper. Cuproptosis induces the aggregation of mitochondrial lipoylated proteins, and the loss of iron-sulfur cluster proteins. In neurodegenerative diseases, the pathogenesis and progression of neurological disorders are linked to copper homeostasis. This review summarizes the advances in copper homeostasis and cuproptosis in the nervous system and neurodegenerative diseases. This offers research perspectives that provide new insights into the targeted treatment of neurodegenerative diseases based on cuproptosis.

Keywords

cuproptosis / copper metabolism / copper homeostasis / neurodegeneration / neurodegenerative disease

References

[1]	Pfeiffer CC, Braverman ER. Zinc, the brain, and behavior. Biol Psychiatry, 1982,17(4):513–532
[2]	Festa RA, Thiele DJ. Copper: an essential metal in biology. Curr Biol, 2011,21(21):R877–R883
[3]	Maung MT, Carlson A, Olea-Flores M, et al. The molecular and cellular basis of copper dysregulation and its relationship with human pathologies. FASEB J, 2021,35(9):e21810
[4]	Gromadzka G, Tarnacka B, Flaga A, et al. Copper Dyshomeostasis in Neurodegenerative Diseases-Therapeutic Implications. Int J Mol Sci, 2020,21(23):9259
[5]	Zhao WJ, Fan CL, Hu XM, et al. Regulated Cell Death of Retinal Ganglion Cells in Glaucoma: Molecular Insights and Therapeutic Potentials. Cell Mol Neurobiol, 2023,43(7):3161–3178
[6]	Zhang Q, Hu XM, Zhao WJ, et al. Targeting Necroptosis: A Novel Therapeutic Option for Retinal Degenerative Diseases. Int J Biol Sci, 2023,19(2):658–674
[7]	Wan H, Yan YD, Hu XM, et al. Inhibition of mitochondrial VDAC1 oligomerization alleviates apoptosis and necroptosis of retinal neurons following OGD/R injury. Ann Anat, 2023,247:152049
[8]	Yan WT, Zhao WJ, Hu XM, et al. PANoptosis-like cell death in ischemia/reperfusion injury of retinal neurons. Neural Regen Res, 2023,18(2):357–363
[9]	Tang D, Kang R, Berghe TV, et al. The molecular machinery of regulated cell death. Cell Res, 2019, 29(5):347–364
[10]	Yang YD, Li ZX, Hu XM, et al. Insight into Crosstalk Between Mitophagy and Apoptosis/Necroptosis: Mechanisms and Clinical Applications in Ischemic Stroke. Curr Med Sci, 2022,42(2):237–248
[11]	Yan WT, Yang YD, Hu XM, et al. Do pyroptosis, apoptosis, and necroptosis (PANoptosis) exist in cerebral ischemia? Evidence from cell and rodent studies. Neural Regen Res, 2022,17(8):1761–1768
[12]	Chen XY, Dai YH, Wan XX, et al. ZBP1-Mediated Necroptosis: Mechanisms and Therapeutic Implications. Molecules, 2022,28(1):52
[13]	Chen J, Wang Y, Li M, et al. Netrin-1 Alleviates Early Brain Injury by Regulating Ferroptosis via the PPARy/Nrf2/GPX4 Signaling Pathway Following Subarachnoid Hemorrhage. Transl Stroke Res, 2024,15(1):219–237
[14]	Zhang Q, Wan XX, Hu XM, et al. Targeting Programmed Cell Death to Improve Stem Cell Therapy: Implications for Treating Diabetes and Diabetes-Related Diseases. Front Cell Dev Biol, 2021,9:809656
[15]	Hu XM, Zhang Q, Zhou RX, et al. Programmed cell death in stem cell-based therapy: Mechanisms and clinical applications. World J Stem Cells, 2020,12(8):787–802
[16]	Mou YH, Wang J, Wu JC, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol, 2019,29,12(1):34
[17]	Tsvetkov P, Coy S, Petrova B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science, 2022,375(6586):1254–1261
[18]	An Y, Li S, Huang X, et al. The Role of Copper Homeostasis in Brain Disease. Int J Mol Sci, 2022,23 (22):13850
[19]	Pal A, Rani I, Pawar A, et al. Microglia and Astrocytes in Alzheimer’s Disease in the Context of the Aberrant Copper Homeostasis Hypothesis. Biomolecules, 2021, 11(11):1598
[20]	Cobine PA, Brady DC. Cuproptosis: Cellular and molecular mechanisms underlying copper-induced cell death. Mol Cell, 2022,82(10):1786–1787
[21]	Arredondo M, Nú?ez MT. Iron and copper metabolism. Mol Aspects Med, 2005,26(4–5):313–327
[22]	Nutrition classics. The Journal of Biological Chemistry, Vol. LXXV II, 1928: Iron in nutrition. VII. Copper as a supplement to iron for hemoglobin building in the rat. By E.B. Hart, H. Steenbock, J. Waddell, and C.A. Elvehjem. Nutr Rev, 1987,45(6):181–183
[23]	Khoshbin K, Camilleri M. Effects of dietary components on intestinal permeability in health and disease. Am J Physiol Gastrointest Liver Physiol, 2020,319(5):G589–G608
[24]	Nose Y, Wood LK, Kim BE, et al. Ctr1 is an apical copper transporter in mammalian intestinal epithelial cells in vivo that is controlled at the level of protein stability. J Biol Chem, 2010,285(42):32385–32392
[25]	Lane DJR, Bae DH, Merlot AM, et al. Duodenal cytochrome b (DCYTB) in iron metabolism: an update on function and regulation. Nutrients, 2015,7(4):2274–2296
[26]	Zimnicka AM, Maryon EB, Kaplan JH. Human copper transporter hCTR1 mediates basolateral uptake of copper into enterocytes: implications for copper homeostasis. J Biol Chem, 2007,282(36):26471–26480
[27]	Schuchardt JP, Hahn A. Intestinal Absorption and Factors Influencing Bioavailability of Magnesium-An Update. Curr Nutr Food Sci, 2017,13(4):260–278
[28]	Lutsenko S. Dynamic and cell-specific transport networks for intracellular copper ions. J Cell Sci, 2021, 134(21):jcs240523
[29]	Nyasae L, Bustos R, Braiterman L, et al. Dynamics of endogenous ATP7A (Menkes protein) in intestinal epithelial cells: copper-dependent redistribution between two intracellular sites. Am J Physiol Gastrointest Liver Physiol, 2007,292(4):G1181–G1194
[30]	Liang ZD, Tsai WB, Lee MY, et al. Specificity protein 1 (sp1) oscillation is involved in copper homeostasis maintenance by regulating human high-affinity copper transporter 1 expression. Mol Pharmacol, 2012,81(3):455–464
[31]	Zhao J, Guo S, Schrodi SJ, et al. Cuproptosis and cuproptosis-related genes in rheumatoid arthritis: Implication, prospects, and perspectives. Front Immunol, 2022,13:930278
[32]	Linder MC. Ceruloplasmin and other copper binding components of blood plasma and their functions: an update. Metallomics, 2016,8(9):887–905
[33]	Xie J, Yang Y, Gao Y, et al. Cuproptosis: mechanisms and links with cancers. Mol Cancer, 2023,22(1):46
[34]	Casareno RL, Waggoner D, Gitlin JD. The copper chaperone CCS directly interacts with copper/zinc superoxide dismutase. J Biol Chem, 1998,273(37):23625–23628
[35]	Punter FA, Adams DL, Glerum DM. Characterization and localization of human COX17, a gene involved in mitochondrial copper transport. Hum Genet, 2000,107(1):69–74
[36]	Pierson H, Muchenditsi A, Kim B-E, et al. The Function of ATPase Copper Transporter ATP7B in Intestine. Gastroenterology, 2018,154(1):168–180.e165
[37]	Telianidis J, Hung YH, Materia S, et al. Role of the P-Type ATPases, ATP7A and ATP7B in brain copper homeostasis. Front Aging Neurosci, 2013,5:44
[38]	Liu H, Lai W, Liu X, et al. Exposure to copper oxide nanoparticles triggers oxidative stress and endoplasmic reticulum (ER)-stress induced toxicology and apoptosis in male rat liver and BRL-3A cell. J Hazard Mater, 2021,401:123349
[39]	van Rensburg MJ, van Rooy M, Bester MJ, et al. Oxidative and haemostatic effects of copper, manganese and mercury, alone and in combination at physiologically relevant levels: An ex vivo study. Hum Exp Toxicol, 2019,38(4):419–433
[40]	Comes G, Fernandez-Gayol O, Molinero A, et al. Mouse metallothionein-1 and metallothionein-2 are not biologically interchangeable in an animal model of multiple sclerosis, EAE. Metallomics, 2019,11(2):327–337
[41]	Leary SC, Winge DR, Cobine PA. “Pulling the plug” on cellular copper: the role of mitochondria in copper export. Biochim Biophys Acta, 2009,1793(1):146–153
[42]	Horn D, Barrientos A. Mitochondrial copper metabolism and delivery to cytochrome c oxidase. IUBMB Life, 2008,60(7):421–429
[43]	Pacheu-Grau D, Wasilewski M, Oeljeklaus S, et al. COA6 Facilitates Cytochrome c Oxidase Biogenesis as Thiol-reductase for Copper Metallochaperones in Mitochondria. J Mol Biol, 2020,432(7):2067–2079
[44]	Robinson NJ, Winge DR. Copper metallochaperones. Annu Rev Biochem, 2010,79:537–562
[45]	Jett KA, Leary SC. Building the CuA site of cytochrome c oxidase: A complicated, redox-dependent process driven by a surprisingly large complement of accessory proteins. J Biol Chem, 2018,293(13):4644–4652
[46]	Leary SC. Redox regulation of SCO protein function: controlling copper at a mitochondrial crossroad. Antioxid Redox Signal, 2010,13(9):1403–1416
[47]	Morgada MN, Abriata LA, Cefaro C, et al. Loop recognition and copper-mediated disulfide reduction underpin meta l site assembly of CuA in human cytochrome oxidase. Proc Natl Acad Sci U S A, 2015, 112(38):11771–11776
[48]	Zhou J, Li XY, Liu YJ, et al. Full-coverage regulations of autophagy by ROS: from induction to maturation. Autophagy, 2022,18(6):1240–1255
[49]	Bompiani KM, Tsai CY, Achatz FP, et al. Copper transporters and chaperones CTR1, CTR2, ATOX1, and CCS as determinants of cisplatin sensitivity. Metallomics, 2016,8(9):951–962
[50]	Skopp A, Boyd SD, Ullrich MS, et al. Copper-zinc superoxide dismutase (Sod1) activation terminates interact ion between its copper chaperone (Ccs) and the cytosolic metal-binding domain of the copper importer Ctr1. Biometals, 2019,32(4):695–705
[51]	Gupta A, Lutsenko S. Human copper transporters: mechanism, role in human diseases and therapeutic potential. Future Med Chem, 2009,1(6):1125–1142
[52]	Hamza I, Faisst A, Prohaska J, et al. The metallochaperone Atox1 plays a critical role in perinatal copper homeostasis. Proc Natl Acad Sci USA, 2001,98(12):6848–6852
[53]	Itoh S, Kim HW, Nakagawa O, et al. Novel role of antioxidant-1(Atox1) as a copper-dependent transcription factor involved in cell proliferation. J Biol Chem, 2008,283(14):9157–9167
[54]	Mattie MD, McElwee MK, Freedman JH. Mechanism of copper-activated transcription: activation of AP-1, and the JNK/SAPK and p38 signal transduction pathways. J Mol Biol, 2008,383(5):1008–1018
[55]	Satake H, Suzuki K, Aoki T, et al. Cupric ion blocks NF kappa B activation through inhibiting the signal-induced phosphorylation of I kappa B alpha. Biochem Biophys Res Commun, 1995,216(2):568–573
[56]	Chen L, Li N, Zhang M, et al. APEX2-based Proximity Labeling of Atox1 Identifies CRIP2 as a Nuclear Copper-binding Protein that Regulates Autophagy Activation. Angew Chem Int Ed Engl, 2021,60(48):25346–25355
[57]	An Y, Li S, Huang X, et al. The Role of Copper Homeostasis in Brain Disease. Int J Mol Sci, 2022, 23(22):13850
[58]	Tong X, Tang R, Xiao M, et al. Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research. J Hematol Oncol, 2022,15(1):174
[59]	Tümer Z, M?ller LB. Menkes disease. Eur J Hum Genet, 2010,18(5):511–518
[60]	Cz?onkowska A, Litwin T, Dusek P, et al. Wilson disease. Nat Rev Dis Primers, 2018,4(1):21
[61]	Bush AI. Metals and neuroscience. Curr Opin Chem Biol, 2000,4(2):184–191
[62]	DiDonato M, Narindrasorasak S, Forbes JR, et al. Expression, purification, and metal binding properties of_the N-terminal domain from the wilson disease putative copper-transporting ATPase (ATP7B). J Biol Chem, 1997,272(52):33279–33282
[63]	L?nnerdal B. Intestinal regulation of copper homeostasis: a developmental perspective. Am J Clin Nutr, 2008,88(3):846S-850S
[64]	Aisen P, Enns C, Wessling-Resnick M. Chemistry and biology of eukaryotic iron metabolism. Int J Biochem Cell Biol, 2001,33(10):940–959
[65]	Akil M, Schwartz JA, Dutchak D, et al. The psychiatric presentations of Wilson’s disease. J Neuropsychiatry Clin Neurosci, 1991,3(4):377–382
[66]	Mairet-Coello G, Tury A, Esnard-Feve A, et al. FAD-linked sulfhydryl oxidase QSOX: topographic, cellular, and subcellular immunolocalization in adult rat central nervous system. J Comp Neurol, 2004,473(3):334–363
[67]	Trombley PQ, Horning MS, Blakemore LJ. Interactions between carnosine and zinc and copper: implications for neuromodulation and neuroprotection. Biochemistry (Mosc), 2000,65(7):807–816
[68]	Johnson KA, Conn PJ, Niswender CM. Glutamate receptors as therapeutic targets for Parkinson’s disease. CNS Neurol Disord Drug Targets, 2009,8(6):475–491
[69]	D’Ambrosi N, Rossi L. Copper at synapse: Release, binding and modulation of neurotransmission. Neurochem Int, 2015,90:36–45
[70]	Moriya M, Ho YH, Grana A, et al. Copper is taken up efficiently from albumin and alpha2-macroglobulin by cultured human cells by more than one mechanism. Am J Physiol Cell Physiol, 2008,295(3):C708–C721
[71]	Montes S, Rivera-Mancia S, Diaz-Ruiz A, et al. Copper and copper proteins in Parkinson’s disease. Oxid Med Cell Longev, 2014,2014:147251
[72]	Wu W, Ruan X, Gu C, et al. Blood-cerebrospinal fluid barrier permeability of metals/metalloids and its determinants in pediatric patients. Ecotoxicol Environ Saf, 2023,266:115599
[73]	Scheiber IF, Mercer JFB, Dringen R. Metabolism and functions of copper in brain. Prog Neurobiol, 2014,116:33–57
[74]	Dringen R, Scheiber IF, Mercer JFB. Copper metabolism of astrocytes. Front Aging Neurosci, 2013,5:9
[75]	Howell SB, Safaei R, Larson CA, et al. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol, 2010,77(6):887–894
[76]	Garza-Lombó C, Posadas Y, Quintanar L, et al. Neurotoxicity Linked to Dysfunctional Metal Ion Homeostasis and Xenobiotic Metal Exposure: Redox Signaling and Oxidative Stress. Antioxid Redox Signal, 2018,28(18):1669–1703
[77]	Varela-Nallar L, Toledo EM, Chacón MA, et al. The functional links between prion protein and copper. Biol Res, 2006,39(1):39–44
[78]	Stuerenburg HJ. CSF copper concentrations, blood-brain barrier function, and coeruloplasmin synthesis during the treatment of Wilson’s disease. J Neural Transm (Vienna), 2000,107(3):321–329
[79]	Choi BS, Zheng W. Copper transport to the brain by the blood-brain barrier and blood-CSF barrier. Brain Res, 2009,1248:14–21
[80]	Kaler SG. ATP7A-related copper transport diseases-emerging concepts and future trends. Nat Rev Neurol, 2011,7(1):15–29
[81]	Nishihara E, Furuyama T, Yamashita S, et al. Expression of copper trafficking genes in the mouse brain. Neuroreport, 1998,9(14):3259–3263
[82]	Barber RG, Grenier ZA, Burkhead JL. Copper Toxicity Is Not Just Oxidative Damage: Zinc Systems and Insight from Wilson Disease. Biomedicines, 2021,9(3):316
[83]	Mercer JF, Ambrosini L, Horton S, et al. Animal models of Menkes disease. Adv Exp Med Biol, 1999,448:97–108
[84]	Menkes JH, Alter M, Steigleder GK, et al. A sex-linked recessive disorder with retardation of growth, peculiar hair, and focal cerebral and cerebellar degeneration. Pediatrics, 1962,29:764–779
[85]	M?ller LB, Mogensen M, Horn N. Molecular diagnosis of Menkes disease: genotype-phenotype correlation. Biochimie, 2009,91(10):1273–1277
[86]	Shim H, Harris ZL. Genetic defects in copper metabolism. J Nutr, 2003,133(5 Suppl 1):1527S–1531S
[87]	Kaler SG, Gahl WA, Berry SA, et al. Predictive value of plasma catecholamine levels in neonatal detection of Menkes disease. J Inherit Metab Dis, 1993,16(5):907–908
[88]	Szauter KM, Cao T, Boyd CD, et al. Lysyl oxidase in development, aging and pathologies of the skin. Pathol Biol (Paris), 2005,53(7):448–456
[89]	Royce PM, Camakaris J, Danks DM. Reduced lysyl oxidase activity in skin fibroblasts from patients with Menkes’ syndrome. Biochem J, 1980,192(2):579–586
[90]	Sarkar B, Lingertat Walsh K, Clarke JT. Copper-histidine therapy for Menkes disease. J Pediatr, 1993,123(5):828–830
[91]	George DH, Casey RE. Menkes disease after copper histidine replacement therapy: case report. Pediatr Dev Pathol, 2001,4(3):281–288
[92]	Kim JH, Lee BH, Kim YM, et al. Novel mutations and clinical outcomes of copper-histidine therapy in Menkes disease patients. Metab Brain Dis, 2015,30(1):75–81
[93]	Cumings JN. The copper and iron content of brain and liver in the normal and in hepato-lenticular degeneration. Brain, 1948,71(Pt. 4):410–415
[94]	Przyby?kowski A, Gromadzka G, Chabik G, et al. Liver cirrhosis in patients newly diagnosed with neurological phenotype of Wilson’s disease. Funct Neurol, 2014,29 (1):23–29
[95]	Walshe JM, Potter G. The pattern of the wholebody distribution of radioactive copper (67Cu, 64Cu) in Wilson’s Disease and various control groups. Q J Med, 1977,46(184):445–462
[96]	Horoupian DS, Sternlieb I, Scheinberg IH. Neuropathological findings in penicillamine-treated patients with Wilson’s disease. Clin Neuropathol, 1988,7(2):62–67
[97]	Bertrand E, Lewandowska E, Szpak GM, et al. Neuropathological analysis of pathological forms of astroglia in Wilson’s disease. Folia Neuropathol, 2001,39(2):73–79
[98]	Langwińska-Wo?ko E, Litwin T, Szulborski K, et al. Optical coherence tomography and electrophysiology of retinal and visual pathways in Wilson’s disease. Metab Brain Dis, 2016,31(2):405–415
[99]	Cz?onkowska A, Litwin T, Karliński M, et al. D-penicillamine versus zinc sulfate as first-line therapy for Wilson’s disease. Eur J Neurol, 2014,21(4):599–606
[100]	European Association for Study of L. EASL Clinical Practice Guidelines: Wilson’s disease. J Hepatol, 2012,56(3):671–685
[101]	Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol, 2011,10(9):819–828
[102]	Morris GP, Clark IA, Vissel B. Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer’s disease. Acta Neuropathol Commun, 2014,2:135
[103]	Zhang YL, Wang J, Zhang ZN, et al. The relationship between amyloid-beta and brain capillary endothelial cells in Alzheimer’s disease. Neural Regen Res, 2022,17(11):2355–2363
[104]	Gaggelli E, Kozlowski H, Valensin D, et al. Copper homeostasis and neurodegenerative disorders (Alzheimer’s, prion, and Parkinson’s diseases and amyotrophic lateral sclerosis). Chem Rev, 2006,106 (6):1995–2044
[105]	Atwood CS, Scarpa RC, Huang X, et al. Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. J Neurochem, 2000,75(3):1219–1233
[106]	Newcombe EA, Camats-Perna J, Silva ML, et al. Inflammation: the link between comorbidities, genetics, and Alzheimer’s disease. J Neuroinflammation, 2018, 15(1):276
[107]	Lovell MA, Robertson JD, Teesdale WJ, et al. Copper, iron and zinc in Alzheimer’s disease senile plaques. J Neurol Sci, 1998,158(1):47–52
[108]	Su XY, Wu WH, Huang ZP, et al. Hydrogen peroxide can be generated by tau in the presence of Cu(II). Biochem Biophys Res Commun, 2007,358(2):661–665
[109]	Yu J, Luo X, Xu H, et al. Identification of the key molecules involved in chronic copper exposure-aggravated memory impairment in transgenic mice of Alzheimer’s disease using proteomic analysis. J Alzheimers Dis, 2015,44(2):455–469
[110]	James SA, Volitakis I, Adlard PA, et al. Elevated labile Cu is associated with oxidative pathology in Alzheimer disease. Free Radic Biol Med, 2012,52(2):298–302
[111]	Yu F, Gong P, Hu Z, et al. Cu (II) enhances the effect of Alzheimer’s amyloid-β peptide on microglial activation. J Neuroinflammation, 2015,12:122
[112]	Lu J, Wu Dm, Zheng Yi, et al. Trace amounts of copper exacerbate beta amyloid-induced neurotoxicity in the cholesterol-fed mice through TNF-mediated inflammatory pathway. Brain Behav Immun, 2009,23 (2):193–203
[113]	Rossi-George A, Guo CJ. Copper disrupts S-nitrosothiol signaling in activated BV2 microglia. Neurochem Int, 2016,99:1–8
[114]	Krasemann S, Madore C, Cialic R, et al. The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity, 2017,47(3):566–581.e9
[115]	Chen Y, Chen J, Wei H, et al. Akkermansia muciniphila-Nlrp3 is involved in the neuroprotection of phosphoglycerate mutase 5 deficiency in traumatic brain injury mice. Front Immunol, 2023,14:1172710
[116]	Zhou Z, Shang L, Zhang Q, et al. DTX3L induced NLRP3 ubiquitination inhibit R28 cell pyroptosis in OGD/R injury. Biochim Biophys Acta Mol Cell Res, 2023,1870(3):119433
[117]	He YF, Hu XM, Khan MA, et al. HSF1 Alleviates Brain Injury by Inhibiting NLRP3-Induced Pyroptosis in a Sepsis Model. Mediators Inflamm, 2023,2023:2252255
[118]	Huang Y, Wang S, Huang F, et al. c-FLIP regulates pyroptosis in retinal neurons following oxygen-glucose deprivation/recovery via a GSDMD-mediated pathway. Ann Anat, 2021,235:151672
[119]	Liao LS, Lu S, Yan WT, et al. The Role of HSP90α in Methamphetamine/Hyperthermia-Induced Necroptosis in Rat Striatal Neurons. Front Pharmacol, 2021,12:716394
[120]	Yan WT, Lu S, Yang YD, et al. Research trends, hot spots and prospects for necroptosis in the field of neuroscience. Neural Regen Res, 2021,16(8):1628–1637
[121]	Hu XM, Li ZX, Lin RH, et al. Guidelines for Regulated Cell Death Assays: A Systematic Summary, A Categorical Comparison, A Prospective. Front Cell Dev Biol, 2021,9:634690
[122]	Wakhloo D, Oberhauser J, Madira A, et al. From cradle to grave: neurogenesis, neuroregeneration and neurodegeneration in Alzheimer’s and Parkinson’s diseases. Neural Regen Res, 2022,17(12):2606–2614
[123]	Banjara M, Ghosh C. Sterile Neuroinflammation and Strategies for Therapeutic Intervention. Int J Inflam, 2017,2017:8385961
[124]	Scheiber IF, Dringen R. Astrocyte functions in the copper homeostasis of the brain. Neurochem Int, 2013,62(5):556–565
[125]	Pal A, Vasishta Rk, Prasad R. Hepatic and hippocampus iron status is not altered in response to increased serum ceruloplasmin and serum “free” copper in Wistar rat model for non-Wilsonian brain copper toxicosis. Biol Trace Elem Res, 2013,154(3):403–411
[126]	Qian Y, Zheng Y, Taylor R, et al. Involvement of the molecular chaperone Hspa5 in copper homeostasis in astrocytes. Brain Res, 2012,1447:9–19
[127]	Pike CJ, Cummings BJ, Monzavi R, et al. Betaamyloid-induced changes in cultured astrocytes parallel reactive astrocytosis associated with senile plaques in Alzheimer’s disease. Neuroscience, 1994,63(2):517–531
[128]	DeWitt DA, Perry G, Cohen M, et al. Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer’s disease. Exp Neurol, 1998,149(2):329–340
[129]	Choo XY, Liddell JR, Huuskonen MT, et al. CuII(atsm) Attenuates Neuroinflammation. Front Neurosci, 2018,12:668
[130]	Mandal PK, Saharan S, Tripathi M, et al. Brain glutathione levels—a novel biomarker for mild cognitive impairment and Alzheimer’s disease. Biol psychiatry, 2015,78(10):702–710
[131]	Uttamsingh V, Keller DA, Anders MW. Acylase I-catalyzed deacetylation of N-acetyl-L-cysteine and S-alkyl-N -acetyl-L-cysteines. Chem Res Toxicol, 1998,11(7):800–809
[132]	Ashraf A, So PW. Spotlight on Ferroptosis: Iron-Dependent Cell Death in Alzheimer’s Disease. Front Aging Neurosci, 2020,12:196
[133]	Derry PJ, Hegde ML, Jackson GR, et al. Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer’s disease from a ferroptosis perspective. Prog Neurobiol, 2020,184:101716
[134]	Bush AI. Drug development based on the metals hypothesis of Alzheimer’s disease. J Alzheimers Dis, 2008,15(2):223–240
[135]	Walker FO. Huntington’s disease. Lancet, 2007,369 (9557):218–228
[136]	Arrasate M, Finkbeiner S. Protein aggregates in Huntington’s disease. Exp Neurol, 2012,238(1):1–11
[137]	Dexter DT, Carayon A, Javoy-Agid F, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson’s disease and other neurodegenerative diseases affecting the basal ganglia. Brain, 1991,114(Pt4):1953–1975
[138]	Tabrizi SJ, Ghosh R, Leavitt BR. Huntingtin Lowering Strategies for Disease Modification in Huntington’s Disease. Neuron, 2019,101(5):801–819
[139]	Xiao G, Fan Q, Wang X, et al. Huntington disease arises from a combinatory toxicity of polyglutamine and copper binding. Proc Natl Acad Sci U S A, 2013,110(37):14995–15000
[140]	Fox JH, Kama JA, Lieberman G, et al. Mechanisms of copper ion mediated Huntington’s disease progression. PLoS One, 2007,2(3):e334
[141]	Pamp K, Bramey T, Kirsch M, et al. NAD(H) enhances the Cu (II)-mediated inactivation of lactate dehydrogenase by increasing the accessibility of sulfhydryl groups. Free Radic Res, 2005,39(1):31–40
[142]	Harms L, Meierkord H, Timm G, et al. Decreased N-acetyl-aspartate/choline ratio and increased lactate in the frontal lobe of patients with Huntington’s disease: a proton magnetic resonance spectroscopy study. J Neurol Neurosurg Psychiatry, 1997,62(1):27–30
[143]	Sheline CT, Choi DW. Cu2+ toxicity inhibition of mitochondrial dehydrogenases in vitro and in vivo. Ann Neurol, 2004,55(5):645–653
[144]	Cherny RA, Ayton S, Finkelstein DI, et al. PBT2 Reduces Toxicity in a C. elegans Model of polyQ Aggregation and Extends Lifespan, Reduces Striatal Atrophy and Improves Motor Performance in the R6/2 Mouse Model of Huntington’s Disease. J Huntingtons Dis}, 2012,1(2):211–219
[145]	Boillée S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron, 2006,52(1):39–59
[146]	Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol, 2014,10(11):661–670
[147]	Feldman EL, Goutman SA, Petri S, et al. Amyotrophic lateral sclerosis. Lancet, 2022,400(10360):1363–1380
[148]	Hardiman O, Al-Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers, 2017,3:17071
[149]	Gil-Bea FJ, Aldanondo G, Lasa-Fernández H, et al. Insights into the mechanisms of copper dyshomeostasis in amyotrophic lateral sclerosis. Expert Rev Mol Med, 2017,19:e7
[150]	Son M, Puttaparthi K, Kawamata H, et al. Overexpression of CCS in G93A-SOD1 mice leads to accelerated neurologi cal deficits with severe mitochondrial pathology. Proc Natl Acad Sci USA, 2007,104(14):6072–6077
[151]	Williams JR, Trias E, Beilby PR, et al. Copper delivery to the CNS by CuATSM effectively treats motor neuron disease in SOD(G93A) mice co-expressing the Copper-Chaperone-for-SOD. Neurobiol Dis, 2016,89:1–9
[152]	Cabreiro F, Ackerman D, Doonan R, et al. Increased life span from overexpression of superoxide dismutase in Caenorhabditis elegans is not caused by decreased oxidative damage. Free Radic Biol Med, 2011,51(8):1575–1582
[153]	Enge TG, Ecroyd H, Jolley DF, et al. Longitudinal assessment of metal concentrations and copper isotope ratios in the G93A SOD1 mouse model of amyotrophic lateral sclerosis. Metallomics, 2017,9(2):161–174
[154]	Roos PM, Vesterberg O, Syversen T, et al. Metal concentrations in cerebrospinal fluid and blood plasma from patients with amyotrophic lateral sclerosis. Biol Trace Elem Res, 2013,151(2):159–170
[155]	Hilton JB, Kysenius K, White AR, et al. The accumulation of enzymatically inactive cuproenzymes is a CNS-specific phenomenon of the SOD1G37R mouse model of ALS and can be restored by overexpressing the human copper transporter hCTR1. Exp Neurol, 2018,307:118–128
[156]	Tokuda E, Okawa E, Ono Si. Dysregulation of intracellular copper trafficking pathway in a mouse model of mutant copper/zinc superoxide dismutase-linked familial amyotrophic lateral sclerosis. J Neurochem, 2009,111(1):181–191
[157]	Hottinger AF, Fine EG, Gurney ME, et al. The copper chelator d-penicillamine delays onset of disease and extend s survival in a transgenic mouse model of familial amyotrophic lateral sclerosis. Eur J Neurosci, 1997,9(7):1548–1551
[158]	Tokuda E, Ono Si, Ishige K, et al. Ammonium tetrathiomolybdate delays onset, prolongs survival, and slows progression of disease in a mouse model for amyotrophic lateral sclerosis. Exp Neurol, 2008,213(1):122–128
[159]	Roberts BR, Lim NKH, McAllum EJ, et al. Oral treatment with Cu (II)(atsm) increases mutant SOD1 in vivo but protects motor neurons and improves the phenotype of a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci, 2014,34(23):8021–8031
[160]	Hilton JB, Mercer SW, Lim NKH, et al. CuII(atsm) improves the neurological phenotype and survival of SOD1G93A mice and selectively increases enzymatically active SOD1 in the spinal cord. Sci Rep, 2017,7:42292
[161]	Tokuda E, Okawa E, Watanabe S, et al. Dysregulation of intracellular copper homeostasis is common to transgenic mice expressing human mutant superoxide dismutase-1s regardless of their copper-binding abilities. Neurobiol Dis, 2013,54:308–319
[162]	De Lazzari F, Bubacco L, Whitworth AJ, et al. Superoxide Radical Dismutation as New Therapeutic Strategy in Parkinson’s Disease. Aging Dis, 2018,9(4):716–728
[163]	Reich SG, Savitt JM. Parkinson’s Disease. Med Clin North Am, 2019,103(2):337–350
[164]	Karimi-Moghadam A, Charsouei S, Bell B, et al. Parkinson Disease from Mendelian Forms to Genetic Susceptibility: New Molecular Insights into the Neurodegeneration Process. Cell Mol Neurobiol, 2018,38(6):1153–1178
[165]	Tolosa E, Garrido A, Scholz SW, et al. Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol, 2021,20(5):385–397
[166]	Youdim MB, Ben-Shachar D, Riederer P. Is Parkinson’s disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol Scand Suppl, 1989,126:47–54
[167]	Riederer P, Sofic E, Rausch WD, et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem, 1989,52(2):515–520
[168]	Perry TL, Godin DV, Hansen S. Parkinson’s disease: a disorder due to nigral glutathione deficiency? Neurosci Lett, 1982,33(3):305–310
[169]	Jenner P. Oxidative stress in Parkinson’s disease. Ann Neurol, 2003,53:S26–S36
[170]	Bisaglia M, Mammi S, Bubacco L. Structural insights on physiological functions and pathological effects of alpha-synuclein. FASEB J, 2009,23(2):329–340
[171]	Binolfi A, Rasia RM, Bertoncini CW, et al. Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement. J Am Chem Soc, 2006,128(30):9893–9901
[172]	Dudzik CG, Walter ED, Millhauser GL. Coordination features and affinity of the Cu2+ site in the α-synuclein protein of Parkinson’s disease. Biochemistry, 2011,50 (11):1771–1777
[173]	McDowall JS, Brown DR. Alpha-synuclein: relating metals to structure, function and inhibition. Metallomics, 2016,8(4):385–397
[174]	Anderson JP, Walker DE, Goldstein JM, et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem, 2006,281(40):29739–29752
[175]	Dikiy I, Eliezer D. N-terminal acetylation stabilizes N-terminal helicity in lipid- and micelle-bound α-synuclein and increases its affinity for physiological membranes. J Biol Chem, 2014,289(6):3652–3665
[176]	Mason RJ, Paskins AR, Dalton CF, et al. Copper Binding and Subsequent Aggregation of α-Synuclein Are Modulated by N-Terminal Acetylation and Ablated by the H50Q Missense Mutation. Biochem, 2016,55(34):4737–4741
[177]	Bisaglia M, Bubacco L. Copper Ions and Parkinson’s Disease: Why Is Homeostasis So Relevant? Biomolecules, 2020,10(2):195
[178]	Uitti RJ, Rajput AH, Rozdilsky B, et al. Regional metal concentrations in Parkinson’s disease, other chronic neurological diseases, and control brains. Can J Neurol Sci, 1989,16(3):310–314
[179]	de Freitas LV, da Silva CCP, Ellena J, et al. Structural and vibrational study of 8-hydroxyquinoline-2-carboxaldehyde isonicotinoyl hydrazine-a potential metal-protein attenuating compound (MPAC) for the treatment of Alzheimer’s disease. Spectrochim Acta A Mol Biomol Spectrosc, 2013,116:41–48
[180]	McAllum EJ, Lim NKH, Hickey JL, et al. Therapeutic effects of CuII(atsm) in the SOD1-G37R mouse model of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener, 2013,14(7–8):586–590
[181]	Wang M, Wan H, Wang S, et al. RSK3 mediates necroptosis by regulating phosphorylation of RIP3 in rat retinal ganglion cells. J Anat, 2020,237(1):29–47\r\nGuo LM, Wang Z, Li SP, et al. RIP3/MLKL-mediated neuronal necroptosis induced by methamphetamine at 39°C. Neural Regen Res, 2020,15(5):865–874
[182]	Wang Z, Guo LM, Wang Y, et al. Inhibition of HSP90α protects cultured neurons from oxygen-glucose deprivation induced necroptosis by decreasing RIP3 expression. J Cell Physiol, 2018,233(6):4864–4884
[183]	Chen J, Li M, Liu Z, et al. Molecular mechanisms of neuronal death in brain injury after subarachnoid hemorrhage. Front Cell Neurosci, 2022,16:1025708
[184]	Hunsaker EW, Franz KJ. Emerging Opportunities To Manipulate Metal Trafficking for Therapeutic Benefit. Inorg Chem, 2019,58(20):13528–13545
[185]	Zheng P, Zhou C, Lu L, et al. Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy. J Exp Clin Cancer Res, 2022,41(1):271
[186]	Hasinoff BB, Yadav AA, Patel D, et al. The cytotoxicity of the anticancer drug elesclomol is due to oxidative stress indirectly mediated through its complex with Cu (II). J Inorg Biochem, 2014,137:22–30
[187]	Yang W, Wang Y, Huang Y, et al. 4-Octyl itaconate inhibits aerobic glycolysis by targeting GAPDH to promote cuproptosis in colorectal cancer. Biomed Pharmacother, 2023,159:114301
[188]	Tsvetkov P, Detappe A, Cai K, et al. Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nat Chem Biol, 2019,15(7):681–689
[189]	Solmonson A, DeBerardinis RJ. Lipoic acid metabolism and mitochondrial redox regulation. J Biol Chem, 2018,293(20):7522–7530
[190]	Lutsenko S. Atp7b?/? mice as a model for studies of Wilson’s disease. Biochem Soc Trans, 2008,36(Pt 6):1233–1238
[191]	Ling P, Yang P, Gao X, et al. ROS generation strategy based on biomimetic nanosheets by self-assembly of nanozymes. J Mater Chem B, 2022,10(46):9607–9612
[192]	Xue J, Yang G, Ding H, et al. Role of NSC319726 in ovarian cancer based on the bioinformatics analyses. Onco Targets Ther, 2015,8:3757–3765
[193]	Shimada K, Reznik E, Stokes ME, et al. Copper-Binding Small Molecule Induces Oxidative Stress and Cell-Cycle Arrest in Glioblastoma-Patient-Derived Cells. Cell Chem Biol, 2018,25(5):585–594.e587
[194]	Polishchuk EV, Merolla A, Lichtmannegger J, et al. Activation of Autophagy, Observed in Liver Tissues From Patients With Wilson Disease and From ATP7B-Deficient Animals, Protects Hepatocytes From Copper-Induced Apoptosis. Gastroenterology, 2019,156(4):1173–1189.e1175
[195]	Guo J, Cheng J, Zheng N, et al. Copper Promotes Tumorigenesis by Activating the PDK1-AKT Oncogenic Pathway in a Copper Transporter 1 Dependent Manner. Adv Sci (Weinh), 2021,8(18):e2004303
[196]	Chen GH, Lv W, Xu YH, et al. Functional analysis of MTF-1 and MT promoters and their transcriptional response to zinc (Zn) and copper (Cu) in yellow catfish Pelteobagrus fulvidraco. Chemosphere, 2020,246: 125792
[197]	Hu W, Zhang C, Wu R, et al. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci U S A, 2010,107(16):7455–7460
[198]	Liu J, Liu Y, Wang Y, et al. HMGB1 is a mediator of cuproptosis-related sterile inflammation. Front Cell Dev Biol, 2022,10:996307
[199]	Lu H, Zhou L, Zhang B, et al. Cuproptosis key gene FDX1 is a prognostic biomarker and associated with immune infiltration in glioma. Front Med (Lausanne), 2022,9:939776
[200]	Zhou Y, Xiao D, Jiang X, et al. EREG is the core oncoimmunological biomarker of cuproptosis and mediates the cross-talk between VEGF and CD99 signaling in glioblastoma. J Transl Med, 2023,21(1):28
[201]	Li Y, Yang J, Zhang Q, et al. Copper ionophore elesclomol selectively targets GNAQ/11-mutant uveal melanoma. Oncogene, 2022,41(27):3539–3553
[202]	Lv H, Liu X, Zeng X, et al. Comprehensive Analysis of Cuproptosis-Related Genes in Immune Infiltration and Prognosis in Melanoma. Front Pharmacol, 2022,13:930041
[203]	Xu S, Liu D, Chang T, et al. Cuproptosis-Associated lncRNA Establishes New Prognostic Profile and Predicts Immunotherapy Response in Clear Cell Renal Cell Carcinoma. Front Genet, 2022,13:938259
[204]	Zhang Z, Zeng X, Wu Y, et al. Cuproptosis-Related Risk Score Predicts Prognosis and Characterizes the Tumor Microenvironment in Hepatocellular Carcinoma. Front Immunol, 2022,13:925618
[205]	Yan C, Niu Y, Ma L, et al. System analysis based on the cuproptosis-related genes identifies LIPT 1 as a novel therapy target for liver hepatocellular carcinoma. J Transl Med, 2022,20(1):452
[206]	Bao JH, Lu WC, Duan H, et al. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas. Front Immunol, 2022,13:933973
[207]	Liu H, Tang T. Pan-cancer genetic analysis of cuproptosis and copper metabolism-related gene set. Front Oncol, 2022,12:952290
[208]	Guo B, Yang F, Zhang L, et al. Cuproptosis Induced by ROS Responsive Nanoparticles with Elesclomol and Copper Combined with αPD-L1 for Enhanced Cancer Immunotherapy. Adv Mater, 2023,35(22):e2212267
[209]	Xu Y, Liu SY, Zeng L, et al. An Enzyme-Engineered Nonporous Copper(I) Coordination Polymer Nanoplat form for Cuproptosis-Based Synergistic Cancer Therapy. Adv Mater, 2022,34(43):e2204733
[210]	Li T, Wang D, Meng M, et al. Copper-Coordinated Covalent Organic Framework Produced a Robust Fenton-Like Effect Inducing Immunogenic Cell Death of Tumors. Macromol Rapid Commun, 2023,44(11):e2200929
[211]	Collins JF, Prohaska JR, Knutson MD. Metabolic crossroads of iron and copper. Nutr Rev, 2010,68(3):133–147
[212]	Jhelum P, David S. Ferroptosis: copper-iron connection in cuprizone-induced demyelination. Neural Regen Res, 2022,17(1):89–90
[213]	Gulec S, Collins JF. Molecular mediators governing iron-copper interactions. Annu Rev Nutr, 2014,34:95–116
[214]	Tang D, Chen X, Kang R, et al. Ferroptosis: molecular mechanisms and health implications. Cell Res, 2021,31(2):107–125
[215]	Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol, 2021,22(4):266–282
[216]	Fleming MD, Trenor CC, 3rd, Su MA, et al. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat Genet, 1997,16(4):383–386
[217]	Patel BN, David S. Anovel glycosylphosphatidylinositol-anchored form of ceruloplasmin is expressed by mammalian astrocytes. J Biol Chem, 1997,272(32): 20185–20190
[218]	Mastrogiannaki M, Matak P, Keith B, et al. HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice. J Clin Invest, 2009,119(5):1159–1166
[219]	Ravia JJ, Stephen RM, Ghishan FK, et al. Menkes Copper ATPase (Atp7a) is a novel metal-responsive gene in rat duodenum, and immunoreactive protein is present on brush-border and basolateral membrane domains. J Biol Chem, 2005,280(43):36221–36227
[220]	Ha JH, Doguer C, Collins JF. Consumption of a High-Iron Diet Disrupts Homeostatic Regulation of Intestinal Copper Absorption in Adolescent Mice. Am J Physiol Gastrointest Liver Physiol, 2017,313(4):G535–G360
[221]	Jhelum P, Santos-Nogueira E, Teo W, et al. Ferroptosis Mediates Cuprizone-Induced Loss of Oligodendrocytes and Demyelination. J Neurosci, 2020,40(48):9327–9341
[222]	Yang M, Wu X, Hu J, et al. COMMD10 inhibits HIFlα/CP loop to enhance ferroptosis and radiosensitivity by disrupting Cu-Fe balance in hepatocellular carcinoma. J Hepatol, 2022,76(5):1138–1150
[223]	Ren X, Li Y, Zhou Y, et al. Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis. Redox Biol, 2021,46:102122
[224]	Xue Q, Yan D, Chen X, et al. Copper-dependent autophagic degradation of GPX4 drives ferroptosis. Autophagy, 2023,19(7):1982–1996
[225]	Shen Y, Li D, Liang Q, et al. Cross-talk between cuproptosis and ferroptosis regulators defines the tumor microenvironment for the prediction of prognosis and therapies in lung adenocarcinoma. Front Immunol, 2023,13:1029092
[226]	Li Y, Wang RY, Deng YJ, et al. Molecular characteristics, clinical significance, and cancer immune interactions of cuproptosis and ferroptosis-associated genes in colorectal cancer. Front Oncol, 2022,12:975859
[227]	Zhao C, Zhang Z, Jing T. A novel signature of combing cuproptosis-with ferroptosis-related genes for prediction of prognosis, immunologic therapy responses and drug sensitivity in hepatocellular carcinoma. Front Oncol, 2022,12:1000993
[228]	Gromadzka G, Tarnacka B, Flaga A, et al. Copper Dyshomeostasis in Neurodegenerative Diseases-Therapeutic Implications. Int J Mol Sci, 2020,21(23):9259
[229]	Chen L, Min J, Wang F. Copper homeostasis and cuproptosis in health and disease. Signal Transduct Target Ther, 2022,7(1):378
[230]	Zlatic SA, Vrailas-Mortimer A, Gokhale A, et al. Rare Disease Mechanisms Identified by Genealogical Proteomics of Copper Homeostasis Mutant Pedigrees. Cell Syst, 2018,6(3):368–380.e366
[231]	Bakkar N, Starr A, Rabichow BE, et al. The M1311V variant of ATP7A is associated with impaired trafficking and copper homeostasis in models of motor neuron disease. Neurobiol Dis, 2021,149:105228
[232]	Hartwig C, Méndez GM, Bhattacharjee S, et al. Golgi-Dependent Copper Homeostasis Sustains Synaptic Development and Mitochondrial Content. J Neurosci, 2021,41(2):215–233
[233]	Choi BY, Jang BG, Kim JH, et al. Copper/zinc chelation by clioquinol reduces spinal cord white matter damage and behavioral deficits in a murine MOG-induced multiple sclerosis model. Neurobiol Dis, 2013,54:382–391
[234]	Lai Y, Lin C, Lin X, et al. Identification and immunological characterization of cuproptosis-related molecular clusters in Alzheimer’s disease. Front Aging Neurosci, 2022,14:932676
[235]	Gawande MB, Goswami A, Felpin FX, et al. Cu and Cu-Based Nanoparticles: Synthesis and Applications in Catalysis. Chem Rev, 2016,116(6):3722–3811
[236]	Verma N, Kumar N. Synthesis and Biomedical Applications of Copper Oxide Nanoparticles: An Expanding Horizon. ACS Biomater Sci Eng, 2019,5(3):1170–1188
[237]	Mani VM, Kalaivani S, Sabarathinam S, et al. Copper oxide nanoparticles synthesized from an endophytic fungus Aspergillus terreus: Bioactivity and anti-cancer evaluations. Environ Res, 2021,201:111502
[238]	Imani SM, Ladouceur L, Marshall T, et al. Antimicrobial Nanomaterials and Coatings: Current Mechanisms and Future Perspectives to Control the Spread of Viruses Including SARS-CoV-2. ACS Nano, 2020,14(10):12341–12369
[239]	Brewer GJ. Copper-2 Hypothesis for Causation of the Current Alzheimer’s Disease Epidemic Together with Dietary Changes That Enhance the Epidemic. Chem Res Toxicol, 2017,30(3):763–768
[240]	McCann CJ, Jayakanthan S, Siotto M, et al. Single nucleotide polymorphisms in the human ATP7B gene modify the properties of the ATP7B protein. Metallomics, 2019,11(6):1128–1139
[241]	Clifford RJ, Maryon EB, Kaplan JH. Dynamic internalization and recycling of a metal ion transporter: Cu homeostasis and CTR1, the human Cu+ uptake system. J Cell Sci, 2016,129(8):1711–1721
[242]	Narindrasorasak S, Kulkarni P, Deschamps P, et al. Characterization and copper binding properties of human COMMD1 (MURR1). Biochemistry, 2007,46(11):3116–3128
[243]	Hu XM, Zheng SY, Zhang Q, et al. PANoptosis signaling enables broad immune response in psoriasis: From pathogenesis to new therapeutic strategies. Comput Struct Biotechnol J, 2023,23:64–76
[244]	Yang GJ, Liu H, Ma DL, et al. Rebalancing metal dyshomeostasis for Alzheimer’s disease therapy. J Biol Inorg Chem, 2019,24(8):1159–1170
[245]	Tulinska J, Mikusova ML, Liskova A, et al. Copper Oxide Nanoparticles Stimulate the Immune Response and Decrease Antioxidant Defense in Mice After Six-Week Inhalation. Front Immunol, 2022,13:874253
[246]	Stamenkovi? S, Du?i? T, Stamenkovi? V, et al. Imaging of glial cell morphology, SOD1 distribution and elemental composition in the brainstem and hippocampus of the ALS hSOD1G93A rat. Neuroscience, 2017,357:37–55
[247]	Wen MH, Xie X, Tu J, et al. Generation of a genetically modified human embryonic stem cells expressing fluorescence tagged ATOX1. Stem Cell Res, 2019,41:101631
[248]	Chen H, Xie X, Chen TY. Single-molecule microscopy for in-cell quantification of protein oligomeric stoichiometry. Curr Opin Struct Biol, 2021,66:112–118
[249]	Gupta D, Bhattacharjee O, Mandal D, et al. CRISPR-Cas9 system: A new-fangled dawn in gene editing. Life Sci, 2019,232:116636
[250]	Wang X, Zhou M, Liu Y, et al. Cope with copper: From copper linked mechanisms to copper-based clinical cancer therapies. Cancer Lett, 2023,561:216157
[251]	Parpura V, Heneka MT, Montana V, et al. Glial cells in (patho)physiology. J Neurochem, 2012,121(1):4–27
[252]	Xu MB, Rong PQ, Jin TY, et al. Chinese Herbal Medicine for Wilson’s Disease: A Systematic Review and Meta-Analysis. Front Pharmacol, 2019,10:277
[253]	Simunkova M, Alwasel SH, Alhazza IM, et al. Management of oxidative stress and other pathologies in Alzheimer’s disease. Arch Toxicol, 2019,93(9):2491–2513
[254]	Airoldi C, La Ferla B, D Orazio G, et al. Flavonoids in the Treatment of Alzheimer’s and Other Neurodegenerative Diseases. Curr Med Chem, 2018,25(27):3228–3246
[255]	Wang D, Tian Z, Zhang P, et al. The molecular mechanisms of cuproptosis and its relevance to cardiovascular disease. Biomed Pharmacother, 2023,163:114830